Biotest AG — Earnings Release 2008

Feb 4, 2009

News Details

Ad-hoc | 4 February 2009 14:01

Biotest AG: Biotest records significant growth in sales and earnings, Majority shareholder terminates discussion about shares’ sale

Biotest AG / Preliminary Results/Miscellaneous

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by

DGAP – a company of EquityStory AG.

The issuer is solely responsible for the content of this announcement.

———————————————————————-

Biotest records significant growth in sales and earnings,

Majority shareholder terminates discussion about shares’ sale

Dreieich, 4 February 2009. According to preliminary and unaudited figures,

the Biotest Group recorded sales of EUR 423 million in financial year 2008,

representing an increase of 30% on the previous year (EUR 326.4 million).

Earnings before interest and tax (EBIT) are in the range of EUR 55 million.

Compared to 2007 (EUR 38.5 million) that is an increase by more than 40%.

Excluding the contribution made by the US plasma protein business, which

was consolidated for the first time in 2008 over a 12-month period, sales

grew by 10% and EBIT climbed by more than 23%.

In the Plasma Protein segment, Biotest achieved sales of EUR 339.5 million,

which corresponds to a 37% increase compared with the previous year (EUR

247.0 million). Net of the contribution made by the US business, sales were

up almost 12% on the previous year.

In the Medical Diagnostic segment, sales were 2% higher than in 2007 at EUR

45.2 million (EUR 44.3 million), while in the Microbiological Monitoring

segment, business volume totalled EUR 38.3 million, up 9% on the previous

year’s figure of EUR 35.1 million.

The majority shareholder in Biotest AG, OGEL GmbH, informed the Board of

Managing Directors that it had terminated its discussions regarding the

sales of a major portion of its share block until further notice. OGEL GmbH

gave the reasons for its decision to terminate discussions relating to the

sale of the majority of its shares as the excellent earnings achieved by

Biotest AG in a difficult market environment, the company’s corporate

strategy targeted at reaching long-term goals and the change in market

conditions.

Biotest will publish the final figures for financial year 2008 on 11 March

2009. The Annual Report is scheduled for publication on 23 March 2009.

Disclaimer

This document contains forward-looking statements on overall economic

development as well as on the business, earnings, financial and asset

situation of Biotest AG and its subsidiaries. These statements are based on

current plans, estimates, forecasts and expectations of the company and are

thus subject to risks and elements of uncertainty that could result in

deviation of actual developments from expected developments. The

forward-looking statements are only valid at the time of publication.

Biotest does not intend to update the forward-looking statements and

assumes no obligation to do so.

About Biotest

Biotest AG, Dreieich, Germany, is a company that researches and

manufactures pharmaceutical, biotherapeutic and diagnostic products and has

specialised in immunology and haematology. In its Plasma proteinsegment,

Biotest develops immunoglobulins, clotting factors and albumins based on

human blood plasma. These are used for diseases of the immune system or

haematopoietic system. In the Biotherapeutic segment, Biotest researches

into the clinical development of monoclonal antibodies, including in the

indications of rheumatoid arthritis and blood cancer. The Diagnostic

segment spans reagents and systems for microbiological monitoring and

medical diagnostics which are used, for example, in blood transfusions and

transplants. Biotest has around 1,950 employees worldwide and its shares

are listed in the Frankfurt Stock Exchange’s S-DAX.

Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de

Dr. Michael Ramroth,

Tel: +49 (0) 6103 801-520,

e-mail: michael_ramroth@biotest.de

Fax: +49 (0) 6103 801-347

WKN, ISIN ordinary share: 522720, DE0005227201

WKN, ISIN preference share: 522723, DE0005227235

Listed: Prime Standard/official trading

Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart

04.02.2009 Financial News transmitted by DGAP

———————————————————————-

Language: English

Issuer: Biotest AG

          Landsteinerstraße 5

          63303 Dreieich

          Deutschland

Phone: 0 61 03 – 8 01-0

Fax: 0 61 03 – 8 01-150

E-mail: investor_relations@biotest.de

Internet: http://www.biotest.de

ISIN: DE0005227201, DE0005227235

WKN: 522720, 522723

Indices: SDAX

Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr

          in Berlin, Düsseldorf, Hamburg, Stuttgart

End of News DGAP News-Service

—————————————————————————